|
Statement
| 1.Date of occurrence of the event:2022/08/11
2.Company name:TTY Biopharm Co., Ltd.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of
$384,643 thousands(expressed in NT dollars; unaudited), a consolidated
operating profit of $91,936 thousands, and a consolidated income
before tax of $101,968 thousands in July 2022; net income attributed to
stockholders of the company was $82,908 thousands; EPS is $0.33.
Year-to-date consolidated net sales was $2,587,275 thousands (in NT
dollars; unaudited), a consolidated operating profit was $636,215
thousands and consolidated income before tax was $740,242 thousands
until July 2022; year-to-date net income attributed to stockholders
of the company was $594,578 thousands; EPS is $2.39.
6.Countermeasures:None.
7.Any other matters that need to be specified:The numbers above are unaudited.
In term of the final net sales and profits, quarterly financial reports
audited by independent accountants will prevail.
|
